| Accession | SAMC2467708 |
|---|---|
| Accession in Other Database | GSA-Human: HRS493557 |
| Sample name | R20035977LR01-147 |
| Title | NSCLC sample |
| Sample type | Human sample |
| Organism | Homo sapiens |
| Description | RNA sequencing of NSCLC |
| Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA003549 in the GSA-Human system. |
| Release date | 2024-11-22 |
| BioProject Accession | PRJCA013411 |
| Submitter | Peng Zhang (zhangpeng1121@tongji.edu.cn) |
| Organization | Shanghai Pulmonary Hospital Tongji University |
| Submission date | 2023-06-18 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA003549 (Controlled Access) | The single-arm, phase II trial was registered with ClinicalTrial.gov (NCT04201756) and conducted in Shanghai Pulmonary Hospital. Between July 2020 and February 2022, patients with stage III NSCLC with EGFR mutations were enrolled. Patients received neoadjuvant treatment with Afatinib (40mg once daily for 8 to 16 weeks) and were reassessed every 4 weeks for feasibility of radical resection. The primary endpoint was objective response rate. |